Ratiopharm up for grabs

This article was originally published in The Tan Sheet

12 Jan 2009
News

Executive Summary

The Merckle Group, the parent of German OTC and generic drug firm Ratiopharm, agrees with investors at VEM VV GmbH to arrange for a bridge loan from Merckle's creditor banks in order to sell Ratiopharm. The Jan. 7 decision follows the suicide of Merckle Group founder, Adolf Merckle, which was linked to his and the company's financial crises. The sale likely will take several months, Ratiopharm says

Existing Subscriber? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS102490

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS102490

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Ratiopharm up for grabs

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Ratiopharm up for grabs

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert